Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Roche Media News
Get the latest updates from Roche Media News directly as they happen.
Follow now 312 followers
Latest posts
Last updated about 19 hours ago
Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis
about 19 hours ago
MUSETTE trial was designed to determine whether a higher dose of the...
Roche Annual General Meeting 2025
9 days ago
Shareholders approved all proposals of the Board of Directors Severin Schwan was...
Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference
17 days ago
New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of...
Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity
22 days ago
Agreement allows for a range of potentially best-in-class therapy options as monotherapy...
Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston
27 days ago
The new center will be a hub for both Roche and Genentech...
FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
29 days ago
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III...
Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies
about 1 month ago
First-ever head-to-head trial comparing Xolair and oral immunotherapy (OIT) Results were featured...
CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
about 1 month ago
Columvi plus chemotherapy showed a 41% reduction in the risk of death...
Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology
about 1 month ago
Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in...
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
about 2 months ago
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in...
New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis
about 2 months ago
Nearly half of patients on Gazyva/Gazyvaro plus standard therapy achieved a complete...
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
about 2 months ago
Susvimo is the first and only continuous delivery treatment that offers an...